892P - Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anticancer agents
Ovarian Cancer
Geriatric Oncology
Therapy
Biological Therapy
Presenter Seiko Bun
Citation Annals of Oncology (2014) 25 (suppl_4): iv305-iv326. 10.1093/annonc/mdu338
Authors S. Bun1, M. Yunokawa2, M. Kodaira3, J. Hashimoto2, H. Yamamoto2, C. Shimizu3, Y. Fujiwara2, Y. Makino1, H. Iwase1, K. Tamura2, Y. Hayashi1
  • 1Pharmacy, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2Department Of Breast And Medical Oncology, National Cancer Center Hospital, 1040045 - Tokyo/JP
  • 3Department Of Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP

Abstract

Aim

Patients with epithelial ovarian cancer, fallopian tube cancer, and peritoneal cancer are, in general, highly responsive to chemotherapy, though, there has been no reports on the feasibility in elderly patients of dose-dense paclitaxel (PTX) and carboplatin (CBDCA) therapy (ddTC:PTX:80mg/m2day1.8.15, CBDCA:AUC6 day1 q3wks), which is one of the standard therapies for ovarian cancer.

Methods

We identified patients who were diagnosed with ovarian, fallopian tube, or peritoneal cancer, and received ddTC therapy at National Cancer Center Hospital from April 2003 to April 2013. We assessed the feasibility of ddTC therapy in the elderly group received at least 2 cycles of ddTC in comparison with the control group consists of patients below the age of 70 years under the same conditions. The following endpoints were extracted from the medical records: age at diagnosis, whether blood transfusion was required, performance status (PS), adverse events, and reasons for the discontinuation of chemotherapy. Relative dose intensity (RDI) of PTX, CBDCA, and ddTC were calculated from patients' treatment information.

Results

143 patients (the elderly group: 22, the control group: 121) were analyzed. Median age in the elderly group was 75(70-85) years, while 56(27-69) years in the control. Performance status (PS: 0-1:2-4) was 18:4 in the elderly group and 107:14 in the control. A comparison between these two groups showed no significant differences on the RDI of PTX, CBDCA, and ddTC (0.75 vs 0.83, P = 0.17; 0.80 vs 0.83, P = 0.42; 0.77:0.83, P = 0.196), respectively. Also, there was no significant difference in the discontinuation of chemotherapy (13.6 vs 7.4%, P = 0.397), blood transfusion (27 vs 23%, P = 0.675), and febrile neutropenia (4.5 vs 0.82%, P = 0.285). blood transfusion, and febrile neutropenia. The reasons for the discontinuation of chemotherapy in the elderly group were a patient refusal (n = 1), an ileus (n = 1), and a gastrointestinal perforation (n = 1). No treatment-related death was observed during the treatment.

Conclusions

No significant differences on the RDI of PTX, CBDCA, and ddTC were seen in the comparison between the two groups. Our examination shows that ddTC therapy for the elderly patients with relatively good PS is feasible.

Disclosure

All authors have declared no conflicts of interest.